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Prognosis of HIV Patients Receiving 
Antiretroviral Therapy According to 
CD4 Counts: A Long-term Follow-up 
study in Yunnan, China
Li Ren  1,2,3, Juan Li4, Shiyi Zhou5, Xueshan Xia6, Zhenrong Xie5, Pan Liu7, Yu Xu5, Yuan Qian8, 
Huifeng Zhang2, Litang Ma8, Qiuwei Pan4 & Kunhua Wang  1,5
We aim to evaluate the overall survival and associated risk factors for HIV-infected Chinese patients on 
antiretroviral therapy (ART). 2517 patients receiving ART between 2006 and 2016 were prospectively 
enrolled in Yunnan province. Kaplan-Meier analyses and Cox proportional hazard regression analyses 
were performed. 216/2517 patients died during a median 17.5 (interquartile range [IQR] 6.8–33.2) 
months of follow-up. 82/216 occurred within 6 months of starting ART. Adjusted hazard ratios 
were10.69 (95%CI 2.38–48.02, p = 0.002) for old age, 1.94 (95%CI 1.40–2.69, p < 0.0001) for advanced 
WHO stage, and 0.42 (95%CI 0.27–0.63, p < 0.0001) for heterosexual transmission compared to 
injecting drug users. Surprisingly, adjusted hazard ratios comparing low CD4 counts group (<50 cells/µl) 
with high CD4 counts group (≥500 cells/µl) within six months after starting ART was 20.17 (95%CI 4.62–
87.95, p < 0.0001) and it declined to 3.57 (95%CI 1.10–11.58, p = 0.034) afterwards. Age, WHO stage, 
transmission route are significantly independent risk factors for ART treated HIV patients. Importantly, 
baseline CD4 counts is strongly inversely associated with survival in the first six months; whereas it 
becomes a weak prognostic factor after six months of starting ART.
As estimated by the Chinese health authority1, there were 501,000 people living with human immunodeficiency 
virus (HIV/AIDS) by the end of 2014 in China, accounting for 0.037% of the total population. Despite of a low 
national prevalence rate, the HIV epidemic is severe in some areas of the Southwest China, in particular the 
Yunnan, Sichuan, and Guangxi provinces. Yunnan is the area most affected by HIV/AIDS in China. The epidemic 
has spread from high-risk groups including drug users, sex workers and unsafe blood recipients to the general 
population. With a population of 44 million, officials estimate that this province has 80,000 HIV infected individ-
uals. Antiretroviral drugs in combination of three or more drugs from more than one class, often called “highly 
active antiretroviral therapy (HAART)”, are very effective in suppressing HIV, although do not eradicate the virus. 
Since the first introducing of HAART in the mid-1990s, it has led to an unprecedented decline of mortality caused 
by HIV/AIDS both in the USA2 and Europe3. Because of the great success of HAART in treating HIV/AIDS in 
the developed countries, the World Health Organization (WHO) has promoted a public health approach to scale 
up the access of antiretroviral therapy in resource-limited setting since 20024, 5. As an emergency response to 
save and improve the lives of AIDS patients in China, the China National Free Antiretroviral Treatment Program 
(NFATP) was piloted in 2002 and scaled up in 2003 national wide6, 7. Until 2014, a total of 295,358 patients in 
China have received HAART1, and thus a large proportion of HIV patients have benefited from this program. 
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Based on China national HIV database as well as a few local studies, an increasing coverage of antiretroviral treat-
ment has significantly decreased HIV/AIDS-related mortality8–12.
It is important to identify prognostic factors for survival among HIV-infected patients receiving ART. Based 
on previous studies, the main risk factors for death include baseline low CD4 cell count, old age and advanced 
WHO stage. Among them, CD4 cell count was suggested as the most important prognostic factor based on the 
estimated hazard ratio values9–11, 13–21. According to those results, the prognostic value of CD4 cell count seems 
to be well-established. However, a recent study, examining European and North American patients, suggested 
that patients with low baseline CD4 cell count only carry the burden of increased risk of death up to 5 years after 
ART16. This indicated the impersistence of the CD4 cell count on the increased mortality, although no other study 
has reported similar observation. In order to better understand the treatment outcome of HIV patients, we have 
carried out a large prospective cohort study with long-term follow up in China, enrolling patients from Zhaotong, 
a prefecture-level city located in the northeast corner of Yunnan province. In this study, we aim to evaluate the 
overall survival and associated risk factors for the HIV-infected patients on ART in this cohort, with particular 
focus on the prognostic value of CD4 cell count.
Results
Baseline Characteristics. A total of 2517 patients (adult) before starting ART were enrolled between July 
2006 and April 2016 in this study. The baseline characteristics of the study population at start of ART are summa-
rized in Table 1. Patients had a median age of 39 (interquartile range 31–50) years. The number of male patients 
accounted for 59.9% of all patients. A total of 76.2% patients were married. As for the HIV transmission routes, 
more than two-thirds (71.9%) were infected through heterosexual; whereas 10.5% through injecting drug use 
(IDU). In terms of WHO clinical stage, 78.9% received ART at stage I/II and 20.9% at stage III/IV. When meas-
uring CD4 cell count on continuous scale, CD4 cell count had an overall median 281 (IQR 177-388) per µl. By 
dividing CD4 cell count into subgroups, there are 5% of patients presenting low CD4 cell count (<50 per µl), and 
66.9% presenting high CD4 cell count (≥200 per µl).
Characteristics Overall (n = 2517) LTFU (n = 199)
Non-LTFU 
(n = 2318) p-valued
Gender, no. (%) 0.512a
    Male 1507/2517 (60) 124/199 (62) 1383/2318 (60)
    Female 1010/2517 (40) 75/199 (38) 935/2318 (40)
Marital status, no. (%) 0.004a
    Unmarried 296/2501 (12) 39/197 (20) 257/2304 (11)
    Married 1919/2501 (76) 137/197 (70) 1782/2304 (77)
    Divorced 156/2501 (6) 10/197 (5) 146/2304 (6)
    Widowed 130/2501 (5) 11/197 (6) 119/2304 (5)
Age at ART initiation, year 0.137b
    Mean (SD) 42 (14) 40 (15) 42 (14)
    Median (IQR) 39 (31–50) 36 (29–49) 39 (31–50)
WHO HIV Clinical Stage, 
no. (%) 0.004
a
    Stage I/II 1986/2511 (79) 158/197 (80) 1828/2314 (80)
    Stage III/IV 525/2511 (21) 39/197 (20) 486/2314 (21)
CD4, cells/µl 0.010a
    Median (IQR) 281(177–388) 330 (220–455) 278 (173–383)
    <50 126/2402 (5) 5/179 (3) 121/2223 (1)
    50–199 593/2402 (24) 31/179 (17) 562/2223 (25)
    200–349 895/2402 (37) 67/179 (37) 828/2223 (37)
    350–499 478/2402 (20) 44/179 (25) 434/2223(20)
    ≥500 310/2402 (13) 32/179 (18) 278/2223 (13)
Transmission category, no. (%)
    Injecting drug users 
(IDU) 263/2517 (11) 42/199 (21) 221/2318 (10) <0.0001
a
    Homosexual 54/2517 (2) 3/199 (2) 51/2318 (2)
    Heterosexual 1809/2517 (72) 136/199 (68) 1673/2318 (72)
    Others/unknownc 391/2517 (16) 18/199 (9) 373/2318 (16)
Table 1. Baseline characteristics of the patients according to whether lost to follow up or not. Abbreviations: 
LTFU = lost to follow up; Non-LTFU = not lost to follow up; ART indicates antiretroviral treatment; 
SD = standard deviation; IQR = interquartile range. aIndicates Pearson’s Chi-squared test; bIndicates Welch Two 
Sample t-test; cInclude blood transfusion, mother-to-Child, and others; dBaseline characteristics were compared 
between patients of LTFU and patients without LTFU.
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Cumulative mortality in study population. The crude cumulative mortality for study population is dis-
played in Fig. 1. Their median follow-up time was 17.5 (IQR 6.8–33.2) months. The cumulative probabilities for 
mortality were 9%, 13%, 19%, and 26% at 2 years, 4 years, 6 years, and 8 years, respectively. 8.6% (216/2517) of 
patients died during the follow-up period. Within these patients, 38.0% (82/216) died in their first 6 months. 
Patients who died at their first six months of follow-up period had a median age of 42.0 (IQR 34.3–60.0), 70.7% 
were male, and 57.3% were in advanced WHO clinical stage of III/IV. The continuous CD4 cell count had a base-
line median 140 (IQR 59–236) cells/µl. 25.6% (21/82) patients were in low CD4 cell count stratum (lower than 50 
per µl); while 26.8% (22/82) in high CD4 cell count stratum (200/µl or greater) (supplementary Table S1).
Prognostic values of baseline factors. The associations of baseline factors at start of ART with mortality, 
estimated from crude and adjusted Cox models with time-dependent coefficients for CD4 cell count are shown 
in Table 2. Age and CD4 cell count were significant prognostic factors for survival (p < 0.0001 by log-rank test) 
based on crude survival analysis as shown in Fig. 2 and Supplementary Figure S1. Of note, patients with low CD4 
cell count (<50 cells/µl) had drastically increased risk for mortality at early follow-up time. In multivariate model, 
advanced WHO clinical stage (HR 1.94, 95%CI 1.40–2.69, p < 0.0001) and old age (>75 years) (HR 10.69, 95%CI 
2.38–48.02, p = 0.002) were significantly associated with worse survival; heterosexual mode was associated with 
better survival (HR 0.42, 95%CI 0.27–0.63, p < 0.0001) than injecting drug users. Varying hazard ratios for base-
line CD4 cell count were observed in analysis for different time intervals since the start of ART. For instance, the 
adjusted HRs comparing low CD4 cell count group (<50 cells/µl) with high CD4 cell count group (≥500 cells/
µl) during the first six months was 20.17 (95%CI 4.62–87.95, p < 0.0001), but it became 3.57 (95%CI 1.10–11.58, 
p = 0.034) after the first six months. By comparing those with CD4 cell count (50–199 cells/µl) and high CD4 cell 
count (≥500 cells/µl), significant HRs were found in the two intervals: 5.06 (95%CI 1.20–21.32, p = 0.027) ≤ 0.5 
year and 2.89 (95%CI 1.02–8.04, p = 0.045) > 0.5 year (Table 2). With respect to the model accuracy, concordance 
with 0.791 suggested good predictive performance of the Cox model.
Discussion
This is a large prospective study pioneering the assessment of patient survival and associated risk factors in 
Chinese population with HIV infection receiving ART. We described the treatment outcome and identified base-
line age, WHO clinical stage as independent predictors for patients survival for all time. The low CD4 cell count 
at baseline had a strong inverse association with survival at first six months of starting ART.
The survival benefit from ART have been demonstrated intensively among the HIV infected patients2, 3. A 
high tolerance of ART regimen and fewer regimen switches were found among our patients (Supplementary 
Figure S2). Of the patients who died during the follow-up, more than two thirds occurred within the first six 
months since ART initiation, similar to previous studies11, 14, 22. The patient characteristics between those dead 
at first six months and the entire study population were clearly described in this study. The former group had a 
higher percentage of patients with old age, advanced WHO clinical stage (stage III/IV) and low CD4 cell count 
compared with the entire study population. Thus, poor baseline patient characteristics seem to contribute largely 
to the worse survival, supporting the importance of early diagnosis and treatment11, 14, 15, 23–25. Overall, we feel that 
the first six months of ART is critical for improving survival outcome in HIV-infected patients.
The varying coefficients for CD4 cell count was demonstrated among our patients. Many previous studies only 
reported CD4 cell count as a strong prognostic factor for all time of their study period, but the potential varying 
effects of CD4 cell count on survival were hardly discussed in their studies9, 11, 21, 26, 27. A potential reason could be 
the lack of testing the proportional hazard assumption for Cox model, or such assumption was met in those stud-
ies. Another potential explanation could be the relatively short follow-up time in many previous studies. Taking 
this into consideration, a recent retrospective study with long-term follow-up (more than ten years) from the 
Antiretroviral Therapy Cohort Collaboration (ART-CC) have suggested that the baseline CD4 cell count is less 
prognostic after five years since starting ART16. In other words, the patients with low baseline CD4 cell count, who 
survived the first five years since ART, may expect similar mortality to that of patients with high baseline CD4 cell 
count. In our prospective cohort study, a strong inverse association between baseline CD4 cell count and risk for 
mortality was also observed, but only for the first half year after starting ART. We observed a 10-fold increased 
mortality for low CD4 cell count, which was much higher than the 2.8-fold increase in the ART-CC study16. 
Of note, there are several differences between these two studies, in particular European Americans vs Chinese 
Figure 1. Cumulative morality from all-cause mortality for study population with human immunodeficiency 
virus (HIV) infection receiving antiretroviral therapy (ART). Corresponding numbers at risk at different time-
points have been indicated below the graph.
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population. Another important difference to be noticed is the anti-HIV drugs used in those studies. The patients 
engaged in the ART-CC study received ART between 1996 and 2001; however, our patients have been treated 
since 2006 with the newer anti-HIV drugs. Given the fact that new drugs introduced since 2002 provide a better 
immunological response28, 29, our data might reflect more the treatment effect on HIV infected patients nowadays. 
These factors may contribute to the discrepancies observed between our study and the previous ones. Besides, the 
CD4 cell count at six months after starting ART was also examined in our study for assessing its potential associa-
tion with survival after six months of starting ART. In contrast to values at baseline, the six-month CD4 cell count 
Baseline characteristics
Univariate analysis Multivariate analysis
Hazard ratio (95% 
CI) p value
Hazard ratio (95% 
CI) p value
Gender
    Female 1 (Reference) 1 (Reference)
    Male 1.74 (1.30–2.34) <0.001 1.26 (0.90–1.75) 0.167
Marital status
    Married 1 (Reference) 1 (Reference)
    Unmarried 1.14 (0.78–1.68) 0.506 — —
    Divorced 1.11 (0.64–1.92) 0.706 — —
    Widowed 1.81 (1.05–3.14) 0.033 — —
Age at ART initiation, yeara
    (0,20] 1 (Reference) 1 (Reference)
    (20,25] 1.07 (0.23–4.97) 0.929 0.96 (0.20–4.47) 0.961
    (25,30] 1.47 (0.35–6.21) 0.604 0.83 (0.20–3.63) 0.818
    (30,35] 1.99 (0.48–8.28) 0.344 0.88 (0.21–3.79) 0.872
    (35,40] 2.10 (0.50–8.78) .308 1.05 (0.25–4.47) 0.948
    (40,45] 2.26 (0.53–9.59) .271 1.18 (0.27–5.09) 0.828
    (45,50] 1.81 (0.41–8.11) 0.435 0.77 (0.16–3.60) 0.739
    (50,55] 2.23 (0.49–10.17) 0.302 1.45 (0.31–6.66) 0.636
    (55,60] 4.40 (1.02–18.91) 0.046 2.92 (0.67–12.66) 0.153
    (60,65] 3.71 (0.82–16.57) 0.087 1.84 (0.40–8.51) 0.436
    (65,70] 5.42 (1.20–24.49) 0.028 2.96 (0.64–13.70) 0.165
    (70,75] 6.73 (1.49–30.40) 0.013 2.45 (0.51–11.74) 0.264
    (75,90] 16.25 (3.73–70.85) 0.000 10.69 (2.38–48.02) 0.002
WHO HIV Clinical Stage
    Stage I/II 1 (Reference) 1 (Reference)
    Stage III/IV 3.15 (2.40–4.13) <0.0001 1.92 (1.38–2.66) <0.0001
Transmission
    Injecting drug users (IDU) 1 (Reference) 1 (Reference)
    Homosexual 0.34 (0.08–1.41) 0.137 0.38 (0.09–1.59) 0.184
    Heterosexual 0.60 (0.43–0.84) 0.004 0.42 (0.28–0.64) <0.0001
    Others/unknownb 1.06 (0.71–1.59) 0.771 0.62 (0.38–1.02) 0.060
Baseline CD4, cells/µl
    ≤0.5 years
    ≥500 1 (Reference) 1 (Reference)
    350–499 1.61 (0.31–8.30) 0.569 1.40 (0.27–7.25) 0.685
    200–349 2.53 (0.58–11.07) 0.217 2.14 (0.49–9.39) 0.312
    50–199 8.41 (2.01–35.07) 0.003 5.06 (1.20–21.32) 0.027
    <50 28.51 (6.68–121.60) <0.0001 20.17 (4.62–87.95) <0.0001
    >0.5 years
    ≥500 1 (Reference) 1 (Reference)
    350–499 1.89 (0.62–5.79) 0.267 1.73 (0.56–5.32) 0.338
    200–349 1.91 (0.70–5.35) 0.220 1.71 (0.61–4.81) 0.310
    50–199 3.93 (1.41–10.94) 0.009 2.89 (1.02–8.04) 0.045
    <50 4.94 (1.57–15.57) 0.006 3.57 (1.10–11.58) 0.034
Table 2. Cox proportional hazard regression analyses analyzing all-cause mortality after starting ART. 
Abbreviations: 95% CI = 95% confidence interval; ART = antiretroviral therapy. aThe patient number in 
each age subgroup were the following: (0,20] 50; (20,25] 185; (25,30] 369; (30,35] 383; (35,40] 389; (40,45] 
295; (45,50] 226; (50,55] 158; (55,60] 147; (60,65] 122; (65,70] 80; (70,75] 67; and (75,90] 45. bIncludes blood 
transfusion, mother-to-Child, and others/unknown.
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was strongly associated with the worse survival for the period after six months of ART initiation. Consistently, 
the prognostic value of six-month CD4 cell count has been demonstrated previously30. To be noticed, due to the 
missing values of six-month CD4 cell count among the patients who had survived for six months (displayed in 
Supplementary Figure S3), these data were not shown in this study.
A potential limitation of this study is the lacking of baseline viral load. Although the primary aim of ART is 
to inhibit the viral replication and reduce viral load, the resulted increase of CD4 cell count is the main goal as it 
serves as the most important indicator of immune function in HIV-infected patients. Despite this, WHO clinical 
stage and particularly CD4 cell counts were analyzed. Therefore, the potential bias from not analyzing viral load 
have been largely circumvented by including the analysis of WHO clinical stage and particularly CD4 cell counts. 
Besides, the present study only analyzed the data which were collected at start of ART initiation. Although base-
line CD4 cell count has been proven to be an important predictor for the long-term outcome of ART and patient 
survival19, 31, 32, the dynamics of CD4 cell count across follow-up period could also be very important, deserving 
further investigation.
In conclusion, this is a large prospective study with long-term follow-up investigating the treatment outcome 
and prognostic factors for the HIV-infected patients receiving ART. Baseline characteristics including gender, 
age and WHO clinical stage are significantly associated with all-cause mortality. Importantly, we reported the 
time-dependent coefficients for CD4 cell count over different time intervals among Chinese population. The 
strong inverse association between CD4 cell count and risk for mortality has been demonstrated for the first half 
year after starting ART. However, CD4 cell count at six month has a strong inverse association with survival after 
six months of starting ART.
Methods
Study population. A prospective cohort study was conducted by enrolling HIV patients at start of ART 
between 2006 July to 2016 April in Zhaotong, Yunnan province, China. Patients were enrolled from different 
areas of Zhaotong (a prefecture-level city), including Zhaoyang District, Ludian County, Qiaojia County, Yanjin 
County, Daguan County, Yongshan County, Suijiang County, Zhenxiong County, Yiliang County, Weixin County 
and Shuifu County. All patients were treated based on the criteria of the “National AIDS Free Antiviral Treatment 
Manual”, HIV drug resistance, individual health, and other factors. We collected data on demographics (age, sex, 
marital status, transmission category), histological parameter (WHO clinical stage), and laboratory maker (CD4 
cell count) at baseline when patients initiated ART.
The institutional ethical committee of the First Affiliated Hospital of Kunming Medical University has 
approved this study. Informed consent was obtained from all participants in this study. No personally identifiable 
information was seen and used in our data analysis. All the methods of this study were performed in accordance 
with the guideline and regulation of the institutional ethical committee of the First Affiliated Hospital of Kunming 
Medical University.
Statistical Analysis. All patients were followed up from the date since starting ART until the date of death, 
loss to follow-up, or the end of follow-up. Patients who were lost to follow-up or the event did not occur within 
the study duration were considered as censored cases. For the patients with treatment changes or interruptions, 
we analyzed the data as their intent to continue treatment, same as the other patients.
Figure 2. Cumulative morality from all-cause mortality for study population infected by human 
immunodeficiency virus (HIV) receiving antiretroviral therapy (ART) according to CD4 cell count (p < 0.0001). 
Corresponding numbers at risk at different time-points split by CD4 cell count have been indicated below the 
graph.
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In descriptive statistics, continuous variables were reported as mean with standardized deviation (SD) and 
median with interquartile range (IQR). Categorical variables were reported as number with percentage. A crude 
survival analysis (Kaplan-Meier curve) was utilized to analyze the patients’ survival on ART during 10-year follow 
up. An adjusted survival analysis, Cox proportional hazard regression analysis, was used to evaluate the factors 
related to survival outcome. Variables with a p-value below 0.20 on univariate analysis were included in multivar-
iate analysis33–35. All statistical analyses were performed in R (version 3.3.1)36. Particularly, “survival” package37 
was used for survival analyses. The loss to follow up and not loss to follow up against survival time were plotted 
to depict the their patterns (Supplementary Figure S4). The assumption of proportional hazards was tested both 
statistically (Supplementary Table S2) and graphically (Supplementary Figure S5) using function cox.zph. Besides, 
Concordance was calculated to assess the Cox model accuracy. One of the strengths of Cox model is its ability 
to encompass the time-varying coefficients. A step function was used to analyze the time-dependent effect of 
baseline CD4 cell count over different time intervals after breaking the data set into time dependent parts using 
survSplit function38. P < 0.05 (two-tailed sides) was considered as significant. The R code for performing Cox 
proportional regression analyses in this study is shown in Supplementary Figure S6.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Role of the Funder/Sponsor. The funding organizations had no role in the design and conduct of the 
study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the 
manuscript; and decision to submit the manuscript for publication.
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